NEWS & MEDIA

  • News

News

Home>NEWS & MEDIA>News

Daewoong Pharceutical jumps into a contrast medium market led by global pharmaceutical companies
Day : 2011-05-26

medical abortion

name of abortion pill in u

symbicort inhaler coupon

symbicort generic brand colincochrane.com symbicort generic date

buy naltrexone online cheap

where can i buy naltrexone online movidafm.net buy naltrexone online usa

amoxicillin cost without prescription

amoxicillin prescription no insurance

buy naltrexone online usa

buy naltrexone from trusted pharmacy redirect where can i buy low dose naltrexone

amoxicillin cost without prescription

amoxicillin prescription no insurance blog.jeannettespecglass.com antibiotic without prescription

buy amoxicillin without prescription

amoxicillin price without insurance blog.icuracao.net

buy abortion pill barcelona

buy abortion pill barcelona

abortion pill

buy cheap abortion pill read

nizoral

nizoral

claritin

claritin

lipitor

lipitor online

atarax

atarax

strattera

strattera tinakuhn.com

abortion pill online usa

purchase abortion pill online

where can i go to get an abortion pill

where can i get an abortion pill

how long does the 2nd abortion pill take to work

how long does the medical abortion pill take to work news.bs.kg

most accurate am i pregnant quiz

am i pregnant quiz

prednisolon tabletta

prednisolon 1world2go.com

cheap abortion pill

cheap abortion pill kit online

abortion pill for cheap

cheap abortion methods click

pregnancy week by week calculator

pregnancy calculator

amlodipin teva

amlodipin krka

prednisolon tabletta

prednisolon hutoncallsme.azurewebsites.net

acquistare cialis originale on line

cialis generico prezzo piu basso

generico cialis 5 mg

tadalafil mylan blog.propartsdirect.net

claritin pregnancy breastfeeding

claritin and pregnancy first trimester anvly.com

fluoxetine alcohol headache

fluoxetine alcohol headache

amlodipin actavis

amlodipin krka

alcohol and antidepressants blackouts

antidepressants citalopram and alcohol bvandam.com

where to buy abortion pill online

can i buy the abortion pill over the counter

lexapro pregnancy test

lexapro pregnancy peider.dk

lexapro and weed

lexapro and weed

viagra diskuze

viagra cena apoteka charamin.com

viagra prodej cena

viagra cena apoteka read here

lexapro pregnancy risk category

lexapro and pregnancy birth defects go

tadalafil sandoz

pillola cialis scaduta mablogs.azurewebsites.net

strattera discount

strattera coupon

- Official launch for contrast medium team held on the 26th, to raise new growth power through continuous R&D

- Neovist to be launched in August, and plans to raise a 30 billion won product




Daewoong Pharmaceutical Co., Ltd (President Lee Jong Wook) has started to advance into the contrast medium market, which is currently led by global companies. The first product, Neovist, will be released in August, and the company plans to grow its market to 30 billion won by 2015.


The size of the contrast medium market in Korea is about 230 billion won, of which more than 80% is held by global companies. For this reason, an attempt at market entry by a domestic company has special significance. President Lee Jong Wook said, "We shall change the trend of the current monopolized market, and will do this by actively investing to settle into the market as soon as possible, in consideration of the possibility of explosive growth in the future."


This market, which has increased by over 10% annually, is regarded as a blue ocean with huge market potential. The hyper-aging trend, in which ‘prevention’ is a greater focus than ‘cure,’ may accelerate the demand for contrast medium a great deal.


The product ‘Neovist’ will be the company’s first step into the market. Neovist is a patented CT medium with high safety, purity and yielding rate, which was developed through independent technology. It satisfies USP and EP quality standards, enabling the company to advance into the US, European, Chinese and South East Asian markets. Neovist obtained item permission on Feb. 17, and was approved for insurance medical fee on May 1. 


Daewoong Pharmaceutical made an application for its unique technology to PCT, and plans to make a market entry. A spokesperson said, "With our specialized sales and product competitiveness, we have a chance of success. And we shall continue our R&D for future market share."


 

Prev CG Bio, bond gfatt "CGDBM100 ®" begins orthopedics clinical test
Next License obtained for patch-type narcotic analgesic, "Matrifen"
목록